A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 522-527

  Cutts, Christopher ^a,b   LaCaze, Adam ^a,b   Tett, Susan ^b  

^a Queensland Rural Medical Support Agency   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Audit; Celecoxib; COX 2 inhibitor; NSAID; Prescribing; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONAMIDE; WARFARIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GENERAL PRACTICE; GOUT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL RECORD; NEURALGIA; OSTEOARTHRITIS; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; REPETITIVE STRAIN INJURY; RHEUMATOID ARTHRITIS; RISK FACTOR; SPORT INJURY; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FAMILY PRACTICE; HUMANS; ISOENZYMES; LACTONES; MEDICAL AUDIT; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOARTHRITIS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; QUEENSLAND; RISK FACTORS; RURAL HEALTH; SULFONAMIDES; SULFONES;

EID: 0036434367     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01666.x     Document Type: Article

References (34)

1. Health Insurance Commission. PBS Items Expenditure, February, 2000. Available from: http://www.hic.gov.au/ cgi-bin/broker.exe. Accessed May 26, 2002.
2. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314.
3. Brooks PM, Day RO. Non-steroidal anti-inflammatory drugs: Differences and similarities. N Engl J Med 1991; 324: 1716-1725.
4. Blower AL, Brooks A, Genn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-291.
5. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Supplement 1991; 28: 6-10.
6. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-1899.
7. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in the risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996; 312: 1563-1566.
8. Thomas MC. Diuretics, ACE inhibitors and NSAIDs-the triple whammy. Med J Aust 2000; 172: 184-185.
9. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under-recognised public health problem. Arch Intern Med 2000; 160: 777-784.
10. Brook RD, Kramer MB, Blaxall BC, Bisognano JD. Nonsteroidal anti-inflammatory drugs and hypertension. J Clin Hypertens 2000; 2: 319-323.
11. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double blind comparison. Lancet 1999; 354: 2106-2111.
12. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomised controlled trial. JAMA 1999; 282: 1921-1928.
13. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269-1278.
14. Silverstein F, Faich GH, Golstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-1255.
15. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
16. The Australian COX-2-Specific Inhibitor (CSI) Prescribing Group. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328-331.
17. National Prescribing Service. Prescribing Practice Review Sixteen. National Prescribing Service, December, 2001.
18. United States Food and Drug Administration. Available from: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1-05_gi.doc
19. ADRAC report, Vol. 19, Number 2, June, 2000. Available from: http://www.health.gov.au/tga/docs/html/aadrbltn/aadr0006.htm. Accessed May 26, 2002.
20. ADRAC report, Vol. 20, Number 1. February, 2001. Available from L: http://www.health.gov.au/tga/docs/html/aadrbltn/aadr0102.htm #cele. Accessed May 26, 2002.
21. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.
22. Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust 2000; 173: 274.
23. Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med 2001; 135: 69-70.
24. Jones DB. COX-2 inhibitors. Med J Aust 2001; 174: 368-369.
25. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Safety 2001; 24: 239-247.
26. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159-175.
27. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 254-257.
28. Boers M. NSAIDS and selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222-1223.
29. Burnett AC, Winyard G. Clinical audit at the heart of clinical effectiveness. J Quality Clin Prac 1998; 18: 3-19.
30. Fraser RC, Khunti K, Baker J, Lakhani M. Effective audit in general practice: A method for systematically developing audit protocols containing evidence based review criteria. Br J Gen Pract 1997; 47: 743-746.
31. Piterman L, Nelson M. Clinical audit linking continuing medical education (CME) and practice assessment (PA). Aust Fam Phys 1997; 26(Suppl 2): S91-S95.
32. Cutts C, LaCaze A. Non-steroidal anti-inflammatory prescribing in a convenience sample of general practitioners. Aust Fam Physician 2002.
33. Britt H, Miller G, Valenti L. 'It's different in the bush'. A comparison of general practice activity in metropolitan and rural areas of Australia 1998-2000. AIHW Cat No. GEP, 6th Edition. Canberra: Australian Institute of Health and Welfare, 2001.
34. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997; 26: 755-770.